TRIM3 and breast carcinoma: In the current study, we found that TRIM3 showed significantly higher expression in recurrent ER+ breast cancer than that in non-recurrent ER+ breast cancer, which consistent with the analysis of TRIM3 expression in response to tamoxifen treatment in ER+ breast cancer data obtained from the TCGA (Figs. 1A, B and 6A).